← 產業報告目錄
Rare Disease Clinical Trials Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune and Inflammation, Hematologic Disorders, Musculoskeletal Disorders), Phase (Phase I, II, III, and IV), And Sponsor, By Region, And Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-23頁數 180報告編號 INSIGHTACE-146e7c954d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Rare Disease Clinical Trials Market is positioned for steady expansion, with a projected CAGR of 9.39% from 2024 to 2031.
The Rare Disease Clinical Trials sector involves The lack of medications available to treat rare diseases, advancements in personalized medicine, and cell and gene therapies, which are opening up new pathways for new treatments for rare diseases, ar. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Rare Disease Clinical Trials Market Snapshot
Chapter 4. Global Rare Disease Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Therapeutic Area:
5.2.1. Oncology
5.2.2. Cardiovascular Disorders
5.2.3. Neurological Disorders
5.2.4. Infectious Disease
5.2.5. Genetic Disorders
5.2.6. Autoimmune and Inflammation
5.2.7. Hematologic Disorders
5.2.8. Musculoskeletal Disorders
5.2.9. Others
Chapter 6. Market Segmentation 2: by Phase Estimates & Trend Analysis
6.1. by Phase & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Phase:
6.2.1. Phase I
6.2.2. Phase II
6.2.3. Phase III
6.2.4. Phase IV
Chapter 7. Market Segmentation 3: by Sponsor Estimates & Trend Analysis
7.1. by Sponsor & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Sponsor:
7.2.2. Non-Profit Organizations
7.2.3. Others
Chapter 8. Rare Disease Clinical Trials Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
8.1.2. North America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2023-2031
8.1.3. North America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Sponsor, 2023-2031
8.1.4. North America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.2. Europe
8.2.1. Europe Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
8.2.2. Europe Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2023-2031
8.2.3. Europe Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Sponsor, 2023-2031
8.2.4. Europe Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
8.3.2. Asia Pacific Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2023-2031
8.3.3. Asia-Pacific Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Sponsor, 2023-2031
8.3.4. Asia Pacific Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.4. Latin America
8.4.1. Latin America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
8.4.2. Latin America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2023-2031
8.4.3. Latin America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Sponsor, 2023-2031
8.4.4. Latin America Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2023-2031
8.5.2. Middle East & Africa Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2023-2031
8.5.3. Middle East & Africa Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Sponsor, 2023-2031
8.5.4. Middle East & Africa Rare Disease Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Takeda Pharmaceutical Company;
9.2.2. F. Hoffmann-La Roche Ltd.;
9.2.3. Pfizer, Inc.;
9.2.4. AstraZeneca;
9.2.5. Novartis AG;
9.2.6. LabCorp;
9.2.7. IQVIA, Inc.;
9.2.8. Charles River Laboratories;
9.2.9. Icon PLC;
9.2.10. Parexel International Corporation
9.2.11. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們